1. Home
  2. EYPT vs UPBD Comparison

EYPT vs UPBD Comparison

Compare EYPT & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.36

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Upbound Group Inc.

UPBD

Upbound Group Inc.

HOLD

Current Price

$19.17

Market Cap

1.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYPT
UPBD
Founded
1987
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Diversified Commercial Services
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2005
1996

Fundamental Metrics

Financial Performance
Metric
EYPT
UPBD
Price
$13.36
$19.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$31.80
$32.25
AVG Volume (30 Days)
786.6K
763.2K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
8.25%
EPS Growth
N/A
N/A
EPS
N/A
1.25
Revenue
$7,539,000.00
$4,695,061,000.00
Revenue This Year
N/A
$5.96
Revenue Next Year
$3,115.57
$6.47
P/E Ratio
N/A
$15.66
Revenue Growth
N/A
8.67
52 Week Low
$5.46
$15.82
52 Week High
$19.11
$28.03

Technical Indicators

Market Signals
Indicator
EYPT
UPBD
Relative Strength Index (RSI) 43.22 50.85
Support Level $12.47 $17.05
Resistance Level $13.32 $19.26
Average True Range (ATR) 0.63 0.80
MACD -0.11 0.01
Stochastic Oscillator 27.50 30.92

Price Performance

Historical Comparison
EYPT
UPBD

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: